|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ϸ����T�ܰ�ϸ����ؿ�ԭ4 |
|
ϸ����T�ܰ�ϸ����ؿ�ԭ4-Ig |
|
Ƥ���� |
| ��������������� | |
|
�ֺ����� |
|
Ҷ��٫��У |
|
�·���У |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
ϸ����T�ܰ�ϸ����ؿ�ԭ4��Ƥ����������о���չ
�ֺ�����, Ҷ��٫��У, �·���У
������ҽ��ѧ����ҽԺƤ����
ϸ����T�ܰ�ϸ����ؿ�ԭ4��Tϸ�������һ�ֹ��̼�����,��B7��Ϻ�,ͨ�����Ե���Tϸ������״̬��ά�����������ȶ�.ϸ����T�ܰ�ϸ����ؿ�ԭ4��Tϸ���ϵı�Ｐ�����̬��,����༲���й�.ϸ����T�ܰ�ϸ����ؿ�ԭ4-Ig���Է��B7,��ֹijЩ�����Ľ���,�Ӷ���������ijЩ���������Լ���������.
[2] McCoy KD,Le Gros G.The xole of CTLA-4 in the regulation of T cell im mune responses.Immunol Cell Biol,1999,77(1):1-10.
[3] Vandenborre K,Van Gool SW,Kasran A,et al.Interaction of CTA-4(CD152) with CD80 or CD86 inhibits human T-cell activation.Immunology,1999,98(3):413-421.
[4] Liu MF,Liu HS,Wang CR,et al.Expression of CTL A-4 molecule in peripheral blood T lymphocvtes from patients with systemic lupus erythemato sus.J Clin Immunol,1998,18(6):392-398.
[5] Garcia-Cozar FJ,Molina IJ,Cuadrado MJ,et al.Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus(SLE) patients.Clin Exp Immunol,1996,104(1):72-79.
[6] Matsui T,Kurokawa M,Kobata T,et al.Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases.J Immunol,1999,162(7):4328-4335.
[7] Matsushita M,Tsuchiva N,Shiota M,et al.Lack of a strong assoeiation of CTLA-4 exon I polymorphism with the suseeptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese:an associaation study using a novel variation screening method.Tissue Antigens,1999,54(6):578-584.
[8] Chu EB,Hobbs MV,Wilson CB,et al.Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTL A4Ig.J Immunol,1996,156(3):1262-1268.
[9] Finck BK,Linsley PS,Wofsy D.Treatment of murine lupus with CTLA41g.Science,1994,265(5176):1225-1227.
[10] Abrams JR,Lebwohl MG,Guzzo CA,et al.CTL A4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.J Clin Invest,1999,103(9):1243-1252.
[11] Sayegh MH.Finallly,CTLA4Ig graduates to the clinic.J Clin Invest,1999,103(9):1223-1225.
[12] Kotsa K,Watson PF,Weetman AP.A CTLA-4 gene polvmoqphism is associated with both Graves disease and autoimmmne hypothyroidism.Clin Endocrinol,1997,46(5):551-554.
[13] Kemp EH,Ajjan RA,Waterman EA,et al.Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo.Br J Dermatol,1999,140(I):73-78.
[14] Steiner K,Waase I,Rau T,et al.Enhanced expression of CTLA-4(CD152) on CD4+ T cells in HIV infection.Clin Exp Immunol,1999,115(3):451-457.
[15] de Leval L,Colombi S,Debrus S,et al.CD28-B7 costimulatory blockade by CTLA4Ig delays the development of retrovirus-induced murine AIDS.J Virol,1998,72(6):5285-5290.
[16] Tang A,Judge TA,Nickoloff BJ,et al.Suppression of murine allergic contact dermatitis by CTLA4Ig.Tolerance induction of Th2 responses requires additional blockade of CD40-ligand.J Immunol,1996,157(1):117-125.
[17] Parra E,Varga M,Sigvardsson M,et al.Costimulation of human CD4 +T cells with LFA-3 and B7 induce distinct effects on AP-1 and NF-kappa B tran.scription factors.J Immunol,1995,155(3):1132-1140.